Literature DB >> 29070670

IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling.

Adeola A Obajemu1, Nina Rao1, Kari A Dilley2, Joselin M Vargas1, Faruk Sheikh3, Raymond P Donnelly3, Reed S Shabman2, Eric G Meissner4, Ludmila Prokunina-Olsson1, Olusegun O Onabajo5.   

Abstract

Type III IFNs are important mediators of antiviral immunity. IFN-λ4 is a unique type III IFN because it is produced only in individuals who carry a dG allele of a genetic variant rs368234815-dG/TT. Counterintuitively, those individuals who can produce IFN-λ4, an antiviral cytokine, are also less likely to clear hepatitis C virus infection. In this study, we searched for unique functional properties of IFN-λ4 that might explain its negative effect on hepatitis C virus clearance. We used fresh primary human hepatocytes (PHHs) treated with recombinant type III IFNs or infected with Sendai virus to model acute viral infection and subsequently validated our findings in HepG2 cell line models. Endogenous IFN-λ4 protein was detectable only in Sendai virus-infected PHHs from individuals with the dG allele, where it was poorly secreted but highly functional, even at concentrations < 50 pg/ml. IFN-λ4 acted faster than other type III IFNs in inducing antiviral genes, as well as negative regulators of the IFN response, such as USP18 and SOCS1 Transient treatment of PHHs with IFN-λ4, but not IFN-λ3, caused a strong and sustained induction of SOCS1 and refractoriness to further stimulation with IFN-λ3. Our results suggest unique functional properties of IFN-λ4 that can be important in viral clearance and other clinical conditions.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29070670      PMCID: PMC5698113          DOI: 10.4049/jimmunol.1700807

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier.

Authors:  Helen M Lazear; Brian P Daniels; Amelia K Pinto; Albert C Huang; Sarah C Vick; Sean E Doyle; Michael Gale; Robyn S Klein; Michael S Diamond
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

3.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

4.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

5.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.

Authors:  Ewa Terczyńska-Dyla; Stephanie Bibert; Francois H T Duong; Ilona Krol; Sanne Jørgensen; Emilie Collinet; Zoltán Kutalik; Vincent Aubert; Andreas Cerny; Laurent Kaiser; Raffaele Malinverni; Alessandra Mangia; Darius Moradpour; Beat Müllhaupt; Francesco Negro; Rosanna Santoro; David Semela; Nasser Semmo; Markus H Heim; Pierre-Yves Bochud; Rune Hartmann
Journal:  Nat Commun       Date:  2014-12-23       Impact factor: 14.919

6.  Human interferon-lambda3 is a potent member of the type III interferon family.

Authors:  C Dellgren; H H Gad; O J Hamming; J Melchjorsen; R Hartmann
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

7.  Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.

Authors:  Nikolaus Jilg; Wenyu Lin; Jian Hong; Esperance A Schaefer; David Wolski; James Meixong; Kaku Goto; Cynthia Brisac; Pattranuch Chusri; Dahlene N Fusco; Stephane Chevaliez; Jay Luther; Kattareeya Kumthip; Thomas J Urban; Lee F Peng; Georg M Lauer; Raymond T Chung
Journal:  Hepatology       Date:  2014-02-14       Impact factor: 17.425

8.  Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta.

Authors:  Hélène Bierne; Laetitia Travier; Tanel Mahlakõiv; Ludovic Tailleux; Agathe Subtil; Alice Lebreton; Anupam Paliwal; Brigitte Gicquel; Peter Staeheli; Marc Lecuit; Pascale Cossart
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

9.  Interferon lambda inhibits dengue virus replication in epithelial cells.

Authors:  Helen K Palma-Ocampo; Juan C Flores-Alonso; Verónica Vallejo-Ruiz; Julio Reyes-Leyva; Lilian Flores-Mendoza; Irma Herrera-Camacho; Nora H Rosas-Murrieta; Gerardo Santos-López
Journal:  Virol J       Date:  2015-09-28       Impact factor: 4.099

10.  Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples.

Authors:  Ahmad Amanzada; Waltraut Kopp; Ulrich Spengler; Giuliano Ramadori; Sabine Mihm
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more
  31 in total

1.  Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Authors:  Thomas R O'Brien; Howard A Young; Raymond P Donnelly; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-04-17       Impact factor: 2.607

2.  The immune profile in HIV: A useful signature in future HIV research?

Authors:  Padraig M C McGettrick; Elena Alvarez Barco; Greg Kaminskiy; Patrick W G Mallon
Journal:  Germs       Date:  2018-06-04

3.  Explaining Pathogenicity of Congenital Zika and Guillain-Barré Syndromes: Does Dysregulation of RNA Editing Play a Role?

Authors:  Helen Piontkivska; Noel-Marie Plonski; Michael M Miyamoto; Marta L Wayne
Journal:  Bioessays       Date:  2019-05-20       Impact factor: 4.345

Review 4.  The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.

Authors:  Olusegun O Onabajo; Brian Muchmore; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-06-26       Impact factor: 2.607

5.  Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers.

Authors:  Frank J Jenkins; Tsion Z Minas; Wei Tang; Tiffany H Dorsey; Stefan Ambs
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-04-25       Impact factor: 5.554

6.  IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer.

Authors:  Wei Tang; Tiffany A Wallace; Ming Yi; Cristina Magi-Galluzzi; Tiffany H Dorsey; Olusegun O Onabajo; Adeola Obajemu; Symone V Jordan; Christopher A Loffredo; Robert M Stephens; Robert H Silverman; George R Stark; Eric A Klein; Ludmila Prokunina-Olsson; Stefan Ambs
Journal:  Clin Cancer Res       Date:  2018-07-16       Impact factor: 12.531

Review 7.  The Genetic Association of IFN-λs with Human Inflammatory Disorders Remains a Conundrum.

Authors:  Sreedhar Chinnaswamy; Marek L Kowalski
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

8.  Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor.

Authors:  Olusegun O Onabajo; A Rouf Banday; Megan L Stanifer; Wusheng Yan; Adeola Obajemu; Deanna M Santer; Oscar Florez-Vargas; Helen Piontkivska; Joselin M Vargas; Timothy J Ring; Carmon Kee; Patricio Doldan; D Lorne Tyrrell; Juan L Mendoza; Steeve Boulant; Ludmila Prokunina-Olsson
Journal:  Nat Genet       Date:  2020-10-19       Impact factor: 41.307

9.  Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study.

Authors:  Shahinaz M Gadalla; Youjin Wang; Tao Wang; Olusegun O Onabajo; A Rouf Banday; Adeola Obajemu; Ezgi Karaesman; Lara Sucheston-Campbell; Theresa Hahn; Jennifer A Sees; Stephen R Spellman; Stephanie J Lee; Hormuzd A Katki; Ludmila Prokunina-Olsson
Journal:  Lancet Haematol       Date:  2020-10       Impact factor: 18.959

10.  Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2.

Authors:  Olusegun O Onabajo; A Rouf Banday; Wusheng Yan; Adeola Obajemu; Megan L Stanifer; Deanna M Santer; Oscar Florez-Vargas; Helen Piontkivska; Joselin Vargas; Carmon Kee; D Lorne J Tyrrell; Juan L Mendoza; Steeve Boulant; Ludmila Prokunina-Olsson
Journal:  bioRxiv       Date:  2020-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.